As new treatments extend survival, the threat of SREs increases
The median survival of patients treated with paclitaxel + bevacizumab is more than 2 years—but half of all patients with untreated bone metastases from breast cancer will experience an SRE within 1 year2,4
Median time to first SRE vs median survival in breast cancer2,4
*Median time to first SRE in untreated patients in a clinical trial, excluding
hypercalcemia of malignancy. Median time to first SRE not reached in
patients treated with ZOMETA.
†Median survival of patients treated with paclitaxel + bevacizumab.
